Biopharma Here to Stay: The Long-Term Case for the PBE ETF
PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value,” according to Invesco.
Due to the high priority of rolling out COVID-19 treatments, some PBE components could enjoy top line growth this year and in 2022.
“As with most viruses, developing COVID-19 treatments has been difficult, but several drugs have shown strong enough efficacy to gain regulatory support,” writes Morningstar analyst Damien Conover. “Historically, one of the best ways to control viruses is through vaccines, and we believe the vaccines emerging will significantly lower the need for COVID-19 treatments by 2023 and beyond. Nevertheless, treatments are in high demand currently and are likely to remain so through 2021 and into 2